The Claim
L-carnitine supplementation at 2 or 4 g/day for six months in women with iatrogenic hyperthyroidism has no effect on biochemical markers of bone resorption, including osteocalcin and urinary OH-proline.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In women with thyroid-related bone loss due to medical treatment, taking 2 or 4 grams of L-carnitine daily for six months does not change levels of osteocalcin or urinary OH-proline, which are markers of bone breakdown.
See the scientific wording
L-carnitine supplementation at 2 or 4 g/day for six months in women with iatrogenic hyperthyroidism does not worsen biochemical markers of bone resorption (osteocalcin and urinary OH-proline), suggesting it may not exacerbate thyroid hormone-induced bone turnover.
L-carnitine enters bone and liver cells and stops thyroid hormones from getting into the nucleus. Without access to the nucleus, thyroid hormones cannot turn on genes that tell bone cells to break down bone tissue. This keeps bone breakdown markers like osteocalcin and urinary OH-proline from rising, even when thyroid hormone levels are high.
What the research says
1 studyThis study found that taking L-carnitine didn’t make bone loss worse in women with an overactive thyroid, and might even help protect their bones. So, it supports the idea that L-carnitine is safe for bones in this situation.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.